• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[Cardiovascular risk patient--how much prevention is necessary and rational?].

作者信息

Seiler C

机构信息

Inselspital, Departement Innere Medizin, Kardiologie, Universität Bern.

出版信息

Praxis (Bern 1994). 1998 Jan 28;87(5):135-40, 142, 144.

PMID:9522631
Abstract

Cardiovascular primary prevention may consist of strategies concerning the entire population (population strategy) or individuals at high risk for a cardiovascular event (high risk strategy). Clinicians are mainly involved in the identification and treatment of high risk individuals. Even more so, preventive measures should be focused on patients who are already affected by coronary artery disease (CAD) or other manifestations of atherosclerosis (secondary prevention). According to the beneficial effect anticipated by cardiovascular prevention, there should be a priority list guiding the therapeutic measures: first priority therapy should be reserved for patients with existing CAD, then persons without CAD symptoms at high risk for disease manifestation due to an accumulation of coronary risk factors (hypercholesterolemia, hypertension, smoking, diabetes mellitus, lack of physical activity, adipositas) should be treated. Third priority for preventive therapy for cardiovascular diseases is reserved for asymptomatic 1st degree relatives of CAD patients with an early onset CAD. Fourth priority have persons who are close relatives of high risk individuals, and fifth priority prevention is cardiovascular risk factor assessment in the general population. Estimation of the risk for future cardiovascular events is very important because it provides a rational basis for the necessity and relevance of a treatment strategy. In this review, several therapeutic options for cardiovascular prevention are described and discussed.

摘要

相似文献

1
[Cardiovascular risk patient--how much prevention is necessary and rational?].
Praxis (Bern 1994). 1998 Jan 28;87(5):135-40, 142, 144.
2
[Cholesterolemia control in Spain, 2000. A tool for cardiovascular disease prevention. Ministry of Health and Consumption, Spanish Society of Cardiology and Spanish Society of Arteriosclerosis].[2000年西班牙的胆固醇血症控制。心血管疾病预防工具。卫生与消费部、西班牙心脏病学会和西班牙动脉硬化学会]
Rev Esp Salud Publica. 2000 May-Jun;74(3):215-53.
3
[Impact of primary and secondary prevention on morbidity and mortality of ischemic cardiopathy].
Arch Cardiol Mex. 2002 Jan-Mar;72 Suppl 1:S167-70.
4
From vulnerable plaque to vulnerable patient--Part III: Executive summary of the Screening for Heart Attack Prevention and Education (SHAPE) Task Force report.从易损斑块到易损患者——第三部分:预防心脏病发作筛查与教育(SHAPE)特别工作组报告执行摘要
Am J Cardiol. 2006 Jul 17;98(2A):2H-15H. doi: 10.1016/j.amjcard.2006.03.002. Epub 2006 Jun 12.
5
Current and future directions of cardiovascular risk prediction.心血管风险预测的现状与未来方向。
Am J Cardiol. 2006 Jan 16;97(2A):28A-32A. doi: 10.1016/j.amjcard.2005.11.013. Epub 2005 Dec 1.
6
The prevalence of cardiovascular disease risk factors in patients from Croatian Zagorje County treated at Department of Medicine, Zabok General Hospital from 2000 to 2006.2000年至2006年在扎博克综合医院内科接受治疗的克罗地亚扎戈列县患者心血管疾病危险因素的患病率。
Coll Antropol. 2007 Sep;31(3):709-15.
7
Coronary artery disease and women: applying the guidelines for risk factor management.冠状动脉疾病与女性:应用风险因素管理指南
Can J Cardiol. 2000 Jan;16 Suppl A:5A-10A.
8
[Cardiovascular risk factors and prevention in women: similarities and differences].[女性心血管危险因素与预防:异同]
Ital Heart J Suppl. 2001 Feb;2(2):125-41.
9
[The best of epidemiology and cardiovascular prevention in 2006].《2006年流行病学与心血管疾病预防的最佳实践》
Arch Mal Coeur Vaiss. 2007 Jan;100 Spec No 1:57-64.
10
[Primary and secondary prevention of the acute coronary syndrome].
Hamostaseologie. 2006 May;26(2):158-66; quiz 167-8.